Camp4 Therapeutics (CAMP) Income from Continuing Operations (2023 - 2026)
Camp4 Therapeutics recorded quarterly Income from Continuing Operations of 12161000.0 in Q1 2026, down 0.79% quarter-over-quarter from 12066000.0 in Q4 2025, and up 2.81% year-over-year from 11829155.87 in Q1 2025.
Camp4 Therapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 12161000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 2.81% year-over-year to 12161000.0; the TTM figure through Mar 2026 stood at 50030000.0 (up 3.24% YoY), while the FY2025 annual figure was 50573000.0, up 2.35% from the prior year.
- Income from Continuing Operations came in at 12161000.0 for Q1 2026 at Camp4 Therapeutics, down from 12066000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11696000.0 in Q3 2023 to a low of 13484000.0 in Q3 2024.
- A 4-year average of 12627454.55 and a median of 12512000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations fell 15.29% in 2024 and grew 9.13% in 2025, its largest moves.
- Camp4 Therapeutics' Income from Continuing Operations stood at 12990000.0 in 2023, then decreased by 2.22% to 13279000.0 in 2024, then climbed by 9.13% to 12066000.0 in 2025, then dropped by 0.79% to 12161000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 12161000.0, 12066000.0, and 13228000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Camp4 Therapeutics | 245.89 Mn | 245.89 Mn | - | -12.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.16 Mn |
| Dec 31, 2025 | -12.07 Mn |
| Sep 30, 2025 | -13.23 Mn |
| Jun 30, 2025 | -12.58 Mn |
| Mar 31, 2025 | -12.51 Mn |
| Dec 31, 2024 | -13.28 Mn |
| Sep 30, 2024 | -13.48 Mn |
| Jun 30, 2024 | -12.43 Mn |
| Mar 31, 2024 | -12.48 Mn |
| Dec 31, 2023 | -12.99 Mn |
| Sep 30, 2023 | -11.70 Mn |